Pharmaceutical Industry Information Portal

HomeRegulatory News

Regulatory News

FDA partially suspends study of Curis’ lymphoma drug

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, April 11th announced that the U.S. Food...

PRAC finds no causal link between Comirnaty and Spikevax mRNA COVID-19 vaccines and autoimmune hepatitis

The April 4-7, 2022 Pharmacovigilance Risk Assessment Committee (PRAC) meeting noted no link between COVID vaccines and autoimmune hepatitis (AIH). The PRAC has concluded that...

FDA Approves alpelisib as first and only treatment for PROS, a spectrum of rare conditions

Novartis on Wednesday announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and...

Bioxcell Therapeutics announces FDA approval of IGALMI, the first new acute treatment for schizophrenia or bipolar disorder

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, on Wednesday announced...

Biocon Biologics gets EMA’s backing for Inpremzia

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., announced today the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has...

EU recommendations for seasonal influenza vaccine composition

Every year, EMA's ad hoc Influenza Working Group issues EU recommendations for the composition of seasonal influenza vaccines on the basis of observations by...
spot_img

Expert Articles

spot_img